Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
deals
2
×
gene therapy
life sciences
national blog main
national top stories
new york blog main
2
×
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
startups
2
×
zolgensma
abbvie
adalimumab (humira)
adeno-associated virus
aducanumab
aduro biotech
affordable care act
alexandria venture investments
alez azar
altitude life science ventures
alzheimer's disease
american society of gene and cell therapy
antibiotics
arch venture partners
axial spondyloarthritis
bausch health
biogen
boston university
boulder/denver blog main
boulder/denver top stories
boxer capital
bristol-myers squibb
cancer
cancer immunotherapy
car-t immunotherapy
What
remains
2
×
approval
bio
biogen’s
biopharmaceutical
companies
convo
crude
cutting
despite
drug
earlier
edge
effects
encoded
failures
gene
help
illumina’s
lasting
limited
limits
littered
long
medicine
nabs
nash
new
news
price
progress
promising
push
road
roundup
single
strategy
talk
therapy
therapy’s
Language
Current search:
remains
×
deals
×
" new york blog main "
×
startups
×
@xconomy.com
5 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More